Centralized Sequencing Program, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, Bethesda, Md.
Centralized Sequencing Program, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, Bethesda, Md.
J Allergy Clin Immunol. 2022 Oct;150(4):947-954. doi: 10.1016/j.jaci.2022.06.009. Epub 2022 Jun 24.
BACKGROUND: Prospective genetic evaluation of patients at this referral research hospital presents clinical research challenges. OBJECTIVES: This study sought not only a single-gene explanation for participants' immune-related presentations, but viewed each participant holistically, with the potential to have multiple genetic contributions to their immune phenotype and other heritable comorbidities relevant to their presentation and health. METHODS: This study developed a program integrating exome sequencing, chromosomal microarray, phenotyping, results return with genetic counseling, and reanalysis in 1505 individuals from 1000 families with suspected or known inborn errors of immunity. RESULTS: Probands were 50.8% female, 71.5% were ≥18 years, and had diverse immune presentations. Overall, 327 of 1000 probands (32.7%) received 361 molecular diagnoses. These included 17 probands with diagnostic copy number variants, 32 probands with secondary findings, and 31 probands with multiple molecular diagnoses. Reanalysis added 22 molecular diagnoses, predominantly due to new disease-gene associations (9 of 22, 40.9%). One-quarter of the molecular diagnoses (92 of 361) did not involve immune-associated genes. Molecular diagnosis was correlated with younger age, male sex, and a higher number of organ systems involved. This program also facilitated the discovery of new gene-disease associations such as SASH3-related immunodeficiency. A review of treatment options and ClinGen actionability curations suggest that at least 251 of 361 of these molecular diagnoses (69.5%) could translate into ≥1 management option. CONCLUSIONS: This program contributes to our understanding of the diagnostic and clinical utility whole exome analysis on a large scale.
背景:在这家转诊研究医院对患者进行前瞻性遗传评估带来了临床研究挑战。
目的:本研究不仅寻求参与者免疫相关表现的单一基因解释,而且还全面观察每个参与者,有可能对其免疫表型和与其表现和健康相关的其他可遗传合并症有多种遗传贡献。
方法:本研究开发了一个项目,将外显子组测序、染色体微阵列、表型分析、遗传咨询结果回报以及对 1000 个家庭的 1505 名疑似或已知先天性免疫缺陷个体进行重新分析整合在一起。
结果:先证者女性占 50.8%,≥18 岁的占 71.5%,且具有多样化的免疫表现。总体而言,1000 个先证者中有 327 个(32.7%)获得了 361 个分子诊断。这些诊断包括 17 个具有诊断性拷贝数变异的先证者、32 个具有次要发现的先证者和 31 个具有多种分子诊断的先证者。重新分析增加了 22 个分子诊断,主要是由于新的疾病-基因关联(22 个中的 9 个,占 40.9%)。四分之一的分子诊断(361 个中的 92 个)不涉及与免疫相关的基因。分子诊断与年龄较小、男性和涉及的器官系统数量较多有关。该项目还促进了新的基因-疾病关联的发现,如 SASH3 相关免疫缺陷。对治疗选择和 ClinGen 可操作性分类的回顾表明,361 个分子诊断中有至少 251 个(69.5%)可转化为至少 1 个管理选择。
结论:该项目有助于我们了解大规模外显子组分析的诊断和临床效用。
J Allergy Clin Immunol. 2022-10
N Engl J Med. 2016-6-9
Am J Med Genet B Neuropsychiatr Genet. 2025-6-16
J Exp Med. 2025-5-5
Cureus. 2025-3-10
J Allergy Clin Immunol. 2025-3
Brief Bioinform. 2024-11-22
J Clin Immunol. 2024-11-23
J Clin Immunol. 2021-5
Am J Hum Genet. 2021-4-1
J Allergy Clin Immunol Pract. 2021-2